Guangdong Marubi Biotechnology Co., Ltd.

SHSE:603983 Stock Report

Market Cap: CN¥12.9b

Guangdong Marubi Biotechnology Valuation

Is 603983 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603983 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603983 (CN¥31.6) is trading above our estimate of fair value (CN¥24.66)

Significantly Below Fair Value: 603983 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603983?

Other financial metrics that can be useful for relative valuation.

603983 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.4x
Enterprise Value/EBITDA56.5x
PEG Ratio2.2x

Price to Earnings Ratio vs Peers

How does 603983's PE Ratio compare to its peers?

The above table shows the PE ratio for 603983 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.2x
603235 JiangXi Tianxin Pharmaceutical
23.5xn/aCN¥12.0b
600315 Shanghai Jahwa United
27.8x14.2%CN¥14.8b
003006 Chongqing Baiya Sanitary Products
40.7x22.9%CN¥9.6b
603193 Runben Biotechnology
32.8x22.4%CN¥7.9b
603983 Guangdong Marubi Biotechnology
55.6x25.8%CN¥12.9b

Price-To-Earnings vs Peers: 603983 is expensive based on its Price-To-Earnings Ratio (55.6x) compared to the peer average (31.2x).


Price to Earnings Ratio vs Industry

How does 603983's PE Ratio compare vs other companies in the CN Personal Products Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.9%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.9%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 603983 is expensive based on its Price-To-Earnings Ratio (55.6x) compared to the CN Personal Products industry average (29.4x).


Price to Earnings Ratio vs Fair Ratio

What is 603983's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603983 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio55.6x
Fair PE Ratio30.6x

Price-To-Earnings vs Fair Ratio: 603983 is expensive based on its Price-To-Earnings Ratio (55.6x) compared to the estimated Fair Price-To-Earnings Ratio (30.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603983 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥31.60
CN¥33.43
+5.8%
14.5%CN¥40.40CN¥25.00n/a7
May ’25CN¥30.33
CN¥31.61
+4.2%
17.1%CN¥39.30CN¥23.40n/a7
Apr ’25CN¥29.47
CN¥29.82
+1.2%
21.1%CN¥39.30CN¥22.00n/a8
Mar ’25CN¥31.57
CN¥29.82
-5.6%
21.1%CN¥39.30CN¥22.00n/a8
Feb ’25CN¥29.43
CN¥28.86
-1.9%
21.4%CN¥39.30CN¥22.00n/a8
Jan ’25CN¥25.27
CN¥28.86
+14.2%
21.4%CN¥39.30CN¥22.00n/a8
Dec ’24CN¥26.30
CN¥29.61
+12.6%
19.0%CN¥39.30CN¥23.00n/a8
Nov ’24CN¥27.81
CN¥30.00
+7.9%
22.4%CN¥43.40CN¥22.40n/a8
Oct ’24CN¥24.72
CN¥31.12
+25.9%
21.4%CN¥43.40CN¥22.40n/a8
Sep ’24CN¥27.05
CN¥31.49
+16.4%
23.9%CN¥47.00CN¥23.00n/a8
Aug ’24CN¥29.70
CN¥33.29
+12.1%
28.1%CN¥47.00CN¥22.00n/a9
Jul ’24CN¥32.35
CN¥33.29
+2.9%
28.1%CN¥47.00CN¥22.00n/a9
Jun ’24CN¥34.10
CN¥33.29
-2.4%
28.1%CN¥47.00CN¥22.00n/a9
May ’24CN¥36.24
CN¥30.78
-15.1%
25.8%CN¥43.00CN¥19.30CN¥30.339
Apr ’24CN¥38.15
CN¥30.54
-20.0%
24.8%CN¥40.40CN¥19.30CN¥29.479
Mar ’24CN¥39.14
CN¥30.54
-22.0%
24.8%CN¥40.40CN¥19.30CN¥31.579
Feb ’24CN¥33.27
CN¥30.54
-8.2%
24.8%CN¥40.40CN¥19.30CN¥29.439
Jan ’24CN¥33.74
CN¥28.85
-14.5%
25.7%CN¥40.40CN¥19.30CN¥25.278
Dec ’23CN¥36.82
CN¥27.04
-26.6%
22.2%CN¥40.00CN¥19.30CN¥26.309
Nov ’23CN¥29.44
CN¥24.84
-15.6%
17.0%CN¥31.62CN¥19.30CN¥27.819
Oct ’23CN¥26.01
CN¥24.51
-5.8%
19.4%CN¥31.62CN¥17.00CN¥24.729
Sep ’23CN¥26.36
CN¥24.53
-6.9%
19.3%CN¥31.62CN¥17.00CN¥27.059
Aug ’23CN¥25.25
CN¥24.49
-3.0%
18.9%CN¥31.62CN¥17.00CN¥29.709
Jul ’23CN¥26.21
CN¥24.06
-8.2%
24.7%CN¥34.82CN¥16.00CN¥32.359
Jun ’23CN¥22.86
CN¥24.06
+5.3%
24.7%CN¥34.82CN¥16.00CN¥34.109
May ’23CN¥20.78
CN¥28.80
+38.6%
27.7%CN¥40.50CN¥14.00CN¥36.248

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.